Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

MLA

Varughese, Joyce, et al. “Cervical Carcinomas Overexpress Human Trophoblast Cell-Surface Marker (Trop-2) and Are Highly Sensitive to Immunotherapy with HRS7, a Humanized Monoclonal Anti-Trop-2 Antibody.” American Journal of Obstetrics and Gynecology, vol. 205, no. 6, Dec. 2011, p. 567.e1-7. EBSCOhost, https://doi.org/10.1016/j.ajog.2011.06.093.

APA

Varughese, J., Cocco, E., Bellone, S., Ratner, E., Silasi, D.-A., Azodi, M., Schwartz, P. E., Rutherford, T. J., Buza, N., Pecorelli, S., & Santin, A. D. (2011). Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. American Journal of Obstetrics and Gynecology, 205(6), 567.e1-7. https://doi.org/10.1016/j.ajog.2011.06.093

Chicago

Varughese, Joyce, Emiliano Cocco, Stefania Bellone, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E Schwartz, et al. 2011. “Cervical Carcinomas Overexpress Human Trophoblast Cell-Surface Marker (Trop-2) and Are Highly Sensitive to Immunotherapy with HRS7, a Humanized Monoclonal Anti-Trop-2 Antibody.” American Journal of Obstetrics and Gynecology 205 (6): 567.e1-7. doi:10.1016/j.ajog.2011.06.093.